Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Trial Profile

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZW 49 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Zymeworks
  • Most Recent Events

    • 18 Jun 2019 According to the Zymeworks media release, the company has received an offering which is intended to accelerate this trial.
    • 28 Jan 2019 Status changed from planning to recruiting.
    • 08 Dec 2018 According to a Zymeworks media release, the company has submitted the Investigational New Drug (IND) Application to the US FDA for ZW49 and look forward to start this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top